After becoming the first Icelandic company to list its shares both in the U.S. and Iceland, Alvotech prepares to move to the Nasdaq Main Market in IcelandListing on the Main Market can increase...

On 27 July 2022, Alvotech filed an amendment to the Registration Statement on Form F-1 (the “Preliminary Prospectus”), previously filed on July 14 2022, with the U.S. Securities and Exchange Commission (the “SEC”). This amended registration statement is attached as a PDF.

On 22 July 2022, Alvotech filed a Registration Statement on Form F-1 (the “Preliminary Prospectus”) with the U.S. Securities and Exchange Commission (the “SEC”). This registration statement is attached as a PDF.

Prolia® and Xgeva® (denosumab) are indicated for the treatment of bone disease, with combined sales of nearly US$5.3 billion in 2021 AVT03 (denosumab) is the 4th product in Alvotech’s portfolio to...

On 14 July 2022, Alvotech filed a Registration Statement on Form F-1 (the “Preliminary Prospectus”) with the U.S. Securities and Exchange Commission (the “SEC”). This registration statement is attached as a PDF.

Four new members enhance independence and diversity of Board of Directors Alvotech (NASDAQ and First North Growth Market: ALVO), a global biotech company specialized in the development and...

Alvogen Lux Holdings S.à r.l. (“Alvogen”) and Aztiq Pharma Partners S.à r.l. (“Aztiq”) have each subscribed to 2,500,000 newly issued shares of Alvotech (the “Company”) for a price of $10 per share. The 5,000,000 shares were issued pursuant to the terms of settlement agreements between the Company a

AVT06 is the third biosimilar candidate developed by Alvotech to enter clinical studiesEylea® (aflibercept) is used for the treatment of eye disorders and reached global sales of nearly US$10 billion...

The board of directors of Alvotech (the “Company”) has resolved to increase the Company´s share capital by an amount of two hundred seventy thousand seven hundred twenty-one US dollars and sixty-seven...